Molecular Targeting of Diffuse Large B-cell Lymphoma
弥漫性大 B 细胞淋巴瘤的分子靶向
基本信息
- 批准号:8208201
- 负责人:
- 金额:$ 57.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-20 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAnimalsAntibody FormationB-Cell LymphomasB-LymphocytesBCL1 OncogeneBCL6 geneBTB/POZ DomainBindingBiologicalBiological MarkersBiologyCell DeathCell LineCellsChemicalsClinicClinical ResearchClinical TrialsComplexDNA DamageDataDevelopmentDockingDoseDrug DesignDrug KineticsDrug usageFamilyFollicular LymphomaFundingGene SilencingGene TargetingGoalsHealthHematopathologyHumanIn VitroLymphomaMalignant NeoplasmsMediatingMolecular StructureMolecular TargetMusN-terminalNormal CellOncogenesPathway interactionsPatientsPeptidesPharmaceutical PreparationsPhase II Clinical TrialsProtein FamilyProteinsRegulator GenesRepressionRepressor ProteinsSafetyScientistSpecimenStructure of germinal center of lymph nodeSurfaceTP53 geneToxic effectTranscription Repressor/CorepressorTranslatingUnited StatesWorkcell killingclinical caredesigndisorder subtypeexperiencehuman NCOR1 proteinimprovedin vivoinhibitor/antagonistkillingslarge cell Diffuse non-Hodgkin&aposs lymphomamembermimeticspeptidomimeticsprotein protein interactionresponsetherapeutic targettumor
项目摘要
DESCRIPTION (provided by applicant): BCL6 is the most commonly involved oncogene in B-cell lymphomas, and is expressed constitutively in a majority of patients with two most frequent forms of lymphoma: the diffuse large B-cell lymphomas (DLBCL) and follicular lymphoma (FL). Many of these BCL6 positive tumors require the continued presence of BCL6 in order to maintain their survival. BCL6 is a member of the BTB/POZ family of transcriptional repressors. BCL6 mediates its effects on gene silencing through recruitment of the SMRT, N-CoR and BCoR corepressor proteins. The BTB domain of BCL6 provides an extended groove like surface to which a linear peptide from the SMRT, N-CoR and BCoR corepressor can bind with high affinity. This protein-protein interaction is required for BCL6 to repress critical checkpoint regulatory genes such as ATR and TP53. We hypothesize that drugs designed to occlude the BCL6 BTB domain corepressor binding groove will block the ability of BCL6 to repress its critical target genes and force lymphoma cells to undergo cell death, which could be enhanced by targeting complementary biological pathways. Along these lines, we have developed a peptidomimetic inhibitor of BCL6 called RI-BPI (retro-inverso BCL6 peptidomimetic inhibitor) with favorable potency, pharmacokinetics, toxicity profile and efficacy. The proposal brings together collaborating scientists with expertise in peptidomimetic drug design, lymphoma biology, hematopathology and clinical research. They will leverage their combined experience in these different fields with the goals of 1) Developing chemical-mimetics of RI-BPI, 2) determining the mechanism and efficacy of cell killing of RI-BPI and derivatives alone and in combination in a spectrum of DLBCL cell lines in vitro and in vivo, 3) determining the response of primary DLBCLs to BPI ex vivo and identify biomarkers predictive of response to RI-BPI, and finally 4) to translate BCL6 targeted therapy to the clinic and determine the safety, activity, and optimal dosing of RI-BPI in patients with BCL-6-positive DLBCL. By the end of the funding period, we expect to be moving peptidomimetic BCL6 inhibitor drugs into phase II clinical trials. PUBLIC HEALTH RELEVANCE: B-cell lymphomas are the fourth most common form of cancer in the United States and several subtypes of this disease are incurable. The most common causative oncogene in these tumors is the BCL6 transcriptional repressor protein. This proposal will define the mechanism of action, refine and translate to a clinical trial a specific BCL6 targeted therapy peptidomimetic drug that we predict will have a major impact on improving the clinical care for patients with B-cell lymphomas.
描述(由申请人提供):BCL6是B细胞淋巴瘤中最常见的癌基因,并且在大多数具有两种最常见的淋巴瘤形式的大多数患者中构成表达:弥漫性大B细胞淋巴瘤(DLBCL)和卵泡淋巴瘤(FL)。这些BCL6阳性肿瘤中的许多都需要持续存在BCl6,以维持其生存。 BCL6是BTB/POZ转录阻遏物家族的成员。 Bcl6通过募集SMRT,N-COR和BCOR COREPRESSOR蛋白来介导其对基因沉默的影响。 BCl6的BTB结构域提供了一个延伸的凹槽表面,从SMRT,N-COR和BCOR COREPRESSOR的线性肽可以与高亲和力结合。 Bcl6需要这种蛋白质 - 蛋白质相互作用来抑制关键检查点调节基因,例如ATR和TP53。我们假设旨在阻断Bcl6 BTB结构核心结合凹槽的药物将阻止Bcl6抑制其关键靶基因并迫使淋巴瘤细胞经历细胞死亡的能力,这可以通过靶向互补的生物学途径来增强。沿着这些线路,我们开发了一种Bcl6的肽抑制剂,称为RI-BPI(恢复互联的Bcl6肽抑制剂),具有良好的效力,药代动力学,毒性和功效。该提案汇集了与肽药物设计,淋巴瘤生物学,血肿学和临床研究方面的专业知识的合作。他们将利用自己在这些不同领域的综合经验,其目标是1)开发RI-BPI的化学仿制药,2)单独确定RI-BPI和衍生物的细胞杀死机制和功效RI-BPI,最后4)将BCL6的靶向治疗转化为诊所,并确定BCL-6阳性DLBCL患者RI-BPI的安全性,活性和最佳剂量。到资金期结束时,我们预计将肽型BCL6抑制剂药物转移到II期临床试验中。公共卫生相关性:B细胞淋巴瘤是美国的第四种最常见的癌症形式,该疾病的几种亚型是无法治愈的。这些肿瘤中最常见的致病性癌基因是Bcl6转录抑制剂蛋白。该提案将定义作用机理,完善并转化为临床试验,特定的BCl6靶向治疗肽类药物,我们预测,该药物将对改善B细胞淋巴瘤患者的临床护理产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ARI M. MELNICK其他文献
ARI M. MELNICK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ARI M. MELNICK', 18)}}的其他基金
Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas
SIRT3 治疗侵袭性和难治性淋巴瘤的靶向治疗
- 批准号:
10587454 - 财政年份:2023
- 资助金额:
$ 57.11万 - 项目类别:
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia
项目 2:粘连蛋白复合物作为骨髓性白血病的肿瘤抑制因子
- 批准号:
10402272 - 财政年份:2019
- 资助金额:
$ 57.11万 - 项目类别:
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia
项目 2:粘连蛋白复合物作为骨髓性白血病的肿瘤抑制因子
- 批准号:
10652281 - 财政年份:2019
- 资助金额:
$ 57.11万 - 项目类别:
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia
项目 2:粘连蛋白复合物作为骨髓性白血病的肿瘤抑制因子
- 批准号:
10153722 - 财政年份:2019
- 资助金额:
$ 57.11万 - 项目类别:
Targeting Epigenetic Circuits in B-Cell Lymphomas
靶向 B 细胞淋巴瘤的表观遗传回路
- 批准号:
10472575 - 财政年份:2018
- 资助金额:
$ 57.11万 - 项目类别:
Targeting Epigenetic Circuits in B-Cell Lymphomas
靶向 B 细胞淋巴瘤的表观遗传回路
- 批准号:
10250403 - 财政年份:2018
- 资助金额:
$ 57.11万 - 项目类别:
Targeting Epigenetic Circuits in B-Cell Lymphomas
靶向 B 细胞淋巴瘤的表观遗传回路
- 批准号:
10689293 - 财政年份:2018
- 资助金额:
$ 57.11万 - 项目类别:
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
靶向 EZH2 治疗生发中心衍生的 B 细胞淋巴瘤
- 批准号:
8748763 - 财政年份:2014
- 资助金额:
$ 57.11万 - 项目类别:
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
靶向 EZH2 治疗生发中心衍生的 B 细胞淋巴瘤
- 批准号:
9118893 - 财政年份:2014
- 资助金额:
$ 57.11万 - 项目类别:
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
靶向 EZH2 治疗生发中心衍生的 B 细胞淋巴瘤
- 批准号:
8906833 - 财政年份:2014
- 资助金额:
$ 57.11万 - 项目类别:
相似国自然基金
基于扁颅蝠类群系统解析哺乳动物脑容量适应性减小的演化机制
- 批准号:32330014
- 批准年份:2023
- 资助金额:215 万元
- 项目类别:重点项目
基于供应链视角的动物源性食品中抗微生物药物耐药性传导机制及监管策略研究
- 批准号:72303209
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于基因组数据自动化分析为后生动物类群大规模开发扩增子捕获探针的实现
- 批准号:32370477
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
大型野生动物对秦岭山地森林林下植物物种组成和多样性的影响及作用机制
- 批准号:32371605
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
闸坝建设对河口大型底栖动物功能与栖息地演变的影响-以粤西鉴江口为例
- 批准号:42306159
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Maturation of human humoral immunity through repeat malaria challenges
通过重复疟疾挑战使人体体液免疫成熟
- 批准号:
10720245 - 财政年份:2023
- 资助金额:
$ 57.11万 - 项目类别:
Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections
利用抗体反应预防和治疗尿路感染
- 批准号:
10523527 - 财政年份:2021
- 资助金额:
$ 57.11万 - 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10454419 - 财政年份:2021
- 资助金额:
$ 57.11万 - 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10672258 - 财政年份:2021
- 资助金额:
$ 57.11万 - 项目类别: